Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Fabhalta
Pharma
Novartis’ Fabhalta wins expanded FDA nod in IgAN
Fabhalta is one of three drugs Novartis is developing for the rare kidney disease IgAN.
Angus Liu
Aug 8, 2024 3:18am
Novartis rides IgAN trioka to trial wins in rare kidney diseases
May 28, 2024 11:20am
Novartis touts trial win, nabs priority review for Fabhalta
Apr 15, 2024 4:22pm
AstraZeneca's rare disease add-on therapy Voydeya scores FDA nod
Apr 1, 2024 11:48am
Roche's answer to AstraZeneca PNH drugs nabs China nod
Feb 8, 2024 11:02am
FDA grants Calliditas full nod for kidney disease drug Tarpeyo
Dec 20, 2023 5:24pm
